0.7584 USD
At close May 16, 4:00 PM EDT
After hours
0.7590
+0.0006
0.08%
1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
148.66%
10 years
-90.28%
 

About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Employees: 95

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

139% more call options, than puts

Call options by funds: $595K | Put options by funds: $249K

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

1% less funds holding

Funds holding: 115 [Q3] → 114 (-1) [Q4]

3% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 30

3.14% less ownership

Funds ownership: 27.68% [Q3] → 24.54% (-3.14%) [Q4]

8% less capital invested

Capital invested by funds: $79.1M [Q3] → $72.3M (-$6.72M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
823%
upside
Avg. target
$7
823%
upside
High target
$7
823%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
36% 1-year accuracy
65 / 180 met price target
823%upside
$7
Buy
Maintained
12 May 2025
Chardan Capital
Daniil Gataulin
17% 1-year accuracy
10 / 58 met price target
823%upside
$7
Buy
Maintained
12 May 2025

Financial journalist opinion

Based on 4 articles about OCGN published over the past 30 days

Neutral
Seeking Alpha
1 week ago
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Conference Call Participants Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen's First Quarter 2025 financial results and business update.
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 week ago
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa.
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
2 weeks ago
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
2 weeks ago
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
Neutral
GlobeNewsWire
1 month ago
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy.
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
Neutral
GlobeNewsWire
1 month ago
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Phase 1 study and approved continuation of dosing in the second cohort. OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, with the potential to treat diabetic macular edema (DME).
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
Neutral
Seeking Alpha
2 months ago
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Operator Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three years Completed dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2.
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission.
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Neutral
GlobeNewsWire
2 months ago
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025.
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Charts implemented using Lightweight Charts™